M-2 protocol

01/01/1994 - "The therapeutic efficacy of VBCMP-M2 protocol in multiple myeloma."
01/01/1985 - "These results confirm the efficacy of the M-2 protocol in multiple myeloma with regards to response rate and survival."
11/01/1984 - "Efficacy of the M-2 protocol in previously untreated patients with advanced multiple myeloma."
01/01/1985 - "54 consecutively referred, previously untreated patients with stage II and III multiple myeloma have been treated with the M-2 protocol. "
10/01/1983 - "From September 1975 to December 1981, 63 consecutive untreated patients with multiple myeloma received the Lee M-2 protocol. "

01/01/1991 - "After addition of IFN-alpha to the modified M-2 protocol, a rapid reduction in the level of serum IgA was found and clinical symptoms including bone pain, anaemia and so on were dramatically improved. "

01/15/1991 - "There was no difference in response to the Memorial Hospital M-2 protocol between diploid and aneuploid patients. "
01/15/1991 - "This study demonstrates no correlation between cellular RNA content and response, as previously described for patients treated with vincristine, Adriamycin, and dexamethasone (VAD), but DNA aneuploidy appears to be an adverse prognostic factor in MM patients treated with the M-2 protocol. "

01/01/1988 - "The M-2 protocol produces effective remissions in diffuse well-differentiated lymphocytic lymphoma. "
01/01/1985 - "The M-2 protocol was administered every 5 weeks to 25 patients with stage III and IV chronic lymphocytic leukemia (CLL). "
01/01/1985 - "Combination chemotherapy with the M-2 protocol (BCNU, cyclophosphamide, vincristine, melphalan, and prednisone) for chronic lymphocytic leukemia (stages III and IV)."
11/01/1982 - "The M-2 protocol (vincristine, cyclophosphamide, BCNU, melphalan, and prednisone) was administered monthly to 63 evaluable patients with advanced chronic lymphocytic leukemia. "
11/01/1982 - "Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone)."

01/01/1991 - "The M-2 protocol may be able to produce prolonged survival in the majority of patients with Waldenström's macroglobulinemia. "
01/01/1991 - "Waldenström's macroglobulinemia: long-term results with the M-2 protocol."
01/01/1991 - "Thirty-three patients with symptomatic Waldenström's macroglobulinemia have been treated with the M-2 protocol (BCNU, cyclophosphamide, vincristine, melphalan, and prednisone). "
05/01/1982 - "Fourteen consecutively referred, symptomatic patients with Waldenström's macroglobulinemia (ages 52-87 yr) have been treated with the 5-drug M-2 protocol (BCNU, cyclophosphamide, vincristine, melphalan, and prednisone). "